Novo Nordisk cuts forecasts amid U.S. drug rivalry, but reports strong Q1 results and responds with expanded access and price cuts.
Super Micro cuts 2025 guidance amid customer order delays and economic uncertainty, sending shares lower despite CEO's optimism about AI server technology leadership.
Travelers without REAL ID can still fly, but face additional security measures amid upcoming enforcement deadline.
Novo Nordisk cuts forecasts amid U.S. drug rivalry, but reports strong Q1 results and responds with expanded access and price cuts.
Super Micro cuts 2025 guidance amid customer order delays and economic uncertainty, sending shares lower despite CEO's optimism about AI server technology leadership.
Travelers without REAL ID can still fly, but face additional security measures amid upcoming enforcement deadline.